2017

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia
Boer J, Steeghs E, Marchante J, Boeree A, Beaudoin J, Beverloo H, Kuiper R, Escherich G, van der Velden V, van der Schoot C, de Groot-Kruseman H, Pieters R, den Boer M
ONCOTARGET. 2017;8(3):4618-4628.

Osteonecrosis develops independently from radiological leukemic infiltration of bone in adolescents with acute lymphoblastic leukemia - first findings of the OPAL trial
Krull K, Kunstreich M, Klasen-Sansone J, Kloetgen A, Gruener F, Escherich G, Bleckmann K, Moericke A, Schrappe M, Jorch N, Steinbach D, Classen C, Guggemos A, Kolb R, Klee D, Borkhardt A, Kuhlen M
LEUKEMIA LYMPHOMA. 2017 [Epub ahead of print];1-10.

Genotype-outcome correlations in pediatric AML
Rasche M, von Neuhoff C, Dworzak M, Bourquin J, Bradtke J, Göhring G, Escherich G, Fleischhack G, Graf N, Gruhn B, Haas O, Klingebiel T, Kremens B, Lehrnbecher T, von Stackelberg A, Tchinda J, Zemanova Z, Thiede C, von Neuhoff N, Zimmermann M, Creutzig U, Reinhardt D
LEUKEMIA. 2017 [Epub ahead of print].

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement
Zoghbi A, Zur Stadt U, Winkler B, Müller I, Escherich G
PEDIATR BLOOD CANCER. 2017 [Epub ahead of print].

2016

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol
Driessen E, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li C, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R
LEUKEMIA. 2016;30(5):1184-1187.

Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation
Kloos R, Pieters R, Escherich G, van der Sluis I
PEDIATR BLOOD CANCER. 2016;63(11):1928-34.

Improved nutrition in adolescents and young adults after childhood cancer - INAYA study
Quidde J, von Grundherr J, Koch B, Bokemeyer C, Escherich G, Valentini L, Buchholz D, Schilling G, Stein A
BMC CANCER. 2016;16(1):872.

Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia Treatment: a Delphi consensus
Schmiegelow K, Attarbaschi A, Barzilai S, Escherich G, Frandsen T, Halsey C, Hough R, Jeha S, Kato M, Liang D, Mikkelsen T, Möricke A, Niinimäki R, Piette C, Putti M, Raetz E, Silverman L, Skinner R, Tuckuviene R, van der Sluis I, Zapotocka E
LANCET ONCOL. 2016;17(6):e231-9.

Rapid Capture Next-Generation Sequencing in Clinical Diagnostics of Kinase Pathway Aberrations in B-Cell Precursor ALL
Stadt U, Escherich G, Indenbirken D, Alawi M, Adao M, Horstmann M
PEDIATR BLOOD CANCER. 2016;63(7):1283-6.

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation
van der Sluis I, Vrooman L, Pieters R, Baruchel A, Escherich G, Goulden N, Mondelaers V, de Toledo J, Rizzari C, Silverman L, Whitlock J
HAEMATOLOGICA. 2016;101(3):279-85.

Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy
Vora A, Andreano A, Pui C, Hunger S, Schrappe M, Moericke A, Biondi A, Escherich G, Silverman L, Goulden N, Taskinen M, Pieters R, Horibe K, Devidas M, Locatelli F, Valsecchi M
J CLIN ONCOL. 2016;34(9):919-26.

The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia
Wojtuszkiewicz A, Assaraf Y, Hoekstra M, Sciarrillo R, Jansen G, Peters G, Pieters R, Sonneveld E, Escherich G, Kaspers G, Cloos J
HAEMATOLOGICA. 2016;101(7):e291-4.

2015

BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures
Boer J, Marchante J, Evans W, Horstmann M, Escherich G, Pieters R, Den Boer M
HAEMATOLOGICA. 2015;100(9):e354-7.

Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: Prognostic relevance of early and late assessment
Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, Bourquin J, Klingebiel T, Borkhardt A, Cario G, Alten J, Escherich G, Astrahantseff K, Seeger K, Henze G, von Stackelberg A
LEUKEMIA. 2015;29(8):1648-1655.

Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia
Löbel U, Trah J, Escherich G
PEDIATR BLOOD CANCER. 2015;62(3):539-41.

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Pui C, Yang J, Hunger S, Pieters R, Schrappe M, Biondi A, Vora A, Baruchel A, Silverman L, Schmiegelow K, Escherich G, Horibe K, Benoit Y, Izraeli S, Yeoh A, Liang D, Downing J, Evans W, Relling M, Mullighan C
J CLIN ONCOL. 2015;33(27):2938-48.

Psychische Belastungen von Kindern und Jugendlichen nach einer Leukämie oder Lymphomerkrankung
Sautier L, Sarkar S, Petersen M, Mehnert A, Escherich G
PRAX KINDERPSYCHOL K. 2015;64(4):273-289.

Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia
Wojtuszkiewicz A, Peters G, van Woerden N, Dubbelman B, Escherich G, Schmiegelow K, Sonneveld E, Pieters R, van de Ven P, Jansen G, Assaraf Y, Kaspers G, Cloos J
HEMATOL ONCOL. 2015;8:61.

2014

EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion
Ariës I, Jerchel I, van den Dungen R, van den Berk L, Boer J, Horstmann M, Escherich G, Pieters R, den Boer M
LEUKEMIA. 2014;28(9):1828-1837.

Acute lymphoblastic leukemia in children with Down Syndrome: a retrospective analysis from the Ponte di Legno study group
Buitenkamp T, Izraeli S, Zimmermann M, Forestier E, Heerema N, van den Heuvel-Eibrink M, Pieters R, Korbijn C, Silverman L, Schmiegelow K, Liang D, Horibe K, Arico M, Biondi A, Basso G, Rabin K, Schrappe M, Cario G, Mann G, Morak M, Panzer-Grümayer R, Mondelaers V, Lammens T, Cavé H, Stark B, Ganmore I, Moorman A, Vora A, Hunger S, Pui C, Mullighan C, Manabe A, Escherich G, Kowalczyk J, Whitlock J, Zwaan C
BLOOD. 2014;123(1):70-77.

Significantly increased CD70 up regulation on TEL-AML positive B cell precursor acute lymphoblastic leukemia cells following CD40 stimulation
Troeger A, Glouchkova L, Ackermann B, Escherich G, Hanenberg H, Janka G, Roettgers S, Göbel U, Dilloo D
KLIN PADIATR. 2014;226(6-7):332-337.

Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia
van der Veer A, van der Velden V, Willemse M, Hoogeveen P, Petricoin E, Beverloo H, Escherich G, Horstmann M, Pieters R, den Boer M
BLOOD CANCER J. 2014;4:e181.

2013

PGK1 as predictor of CXCR4 expression, bone marrow metastases and survival in neuroblastoma
Ameis H, Drenckhan A, Loga K, Escherich G, Wenke K, Izbicki J, Reinshagen K, Gros S
PLOS ONE. 2013;8(12):e83701.

Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence
Bonn B, Rohde M, Zimmermann M, Krieger D, Oschlies I, Niggli F, Wrobel G, Attarbaschi A, Escherich G, Klapper W, Reiter A, Burkhardt B
BLOOD. 2013;121(16):3153-60.

Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group
Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grümayer R, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Schrauder A, Escherich G, Sramkova L, Niggli F, Hitzler J, von Stackelberg A
J CLIN ONCOL. 2013;31(21):2736-42.

Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C, von Stackelberg A, Seeger K, Groeneveld T, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G
EUR J CANCER. 2013;49(6):1346-1355.

Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.
Escherich G, Zimmermann M, Janka-Schaub G
PEDIATR BLOOD CANCER. 2013;60(2):254-257.

Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial
Escherich G, Zur Stadt U, Zimmermann M, Horstmann M
BRIT J HAEMATOL. 2013;163(2):240-7.

Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia
Hartz B, Löbel U, Hagel C, Escherich G
AM J HEMATOL. 2013;88(12):1096-7.

Denosumab
Lange T, Stehling C, Fröhlich B, Klingenhöfer M, Kunkel P, Schneppenheim R, Escherich G, Gosheger G, Hardes J, Jürgens H, Schulte T
EUR SPINE J. 2013;22(6):1417-22.

Refinement of IKZF1 recombination hotspots in pediatric BCP-ALL patients.
Meyer C, Zur Stadt U, Escherich G, Hofmann J, Binato R, Barbosa T, Emerenciano M, Pombo-de-Oliveira M, Horstmann M, Marschalek R
Am J Blood Res. 2013;3(2):165-173.

Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome
Meyr F, Escherich G, Mann G, Klingebiel T, Kulozik A, Rossig C, Schrappe M, Henze G, von Stackelberg A, Hitzler J
BRIT J HAEMATOL. 2013;162(1):98-106.

Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia
Richards S, Pui C, Gayon P
PEDIATR BLOOD CANCER. 2013;60(2):185-95.

Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia
Schmiegelow K, Levinsen M, Attarbaschi A, Baruchel A, Devidas M, Escherich G, Gibson B, Heydrich C, Horibe K, Ishida Y, Liang D, Locatelli F, Michel G, Pieters R, Piette C, Pui C, Raimondi S, Silverman L, Stanulla M, Stark B, Winick N, Valsecchi M
J CLIN ONCOL. 2013;31(19):2469-76.

Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia
van der Sluis I, Möricke A, Escherich G, von Stackelberg A, Holter W, Klingebiel T, Flotho C, Legien S, Tissing W, Bierings M, Guimbal-Schmolck C, Pichlmeier U, Kühnel H, Pieters R
HAEMATOLOGICA. 2013;98(11):1697-701.

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL
van der Veer A, Waanders E, Pieters R, Willemse M, Van Reijmersdal S, Russell L, Harrison C, Evans W, van der Velden V, Hoogerbrugge P, Van Leeuwen F, Escherich G, Horstmann M, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman H, Sonneveld E, Kuiper R, Den Boer M
BLOOD. 2013;122(15):2622-9.

2012

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
Biondi A, Schrappe M, Paola D, Castor A, Lucchini G, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Li C, Vora A, Aricò M, Röttgers S, Saha V, Valsecchi M
LANCET ONCOL. 2012;13(9):936-945.

Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Pauli S, Steinemann D, Dittmann K, Wienands J, Shoukier M, Möschner M, Burfeind P, Manukjan G, Göhring G, Escherich G
AM J MED GENET A. 2012;158A(3):652-658.

Outcomes after induction failure in childhood acute lymphoblastic leukemia.
Schrappe M, Hunger S, Pui C, Saha V, Gaynon P, Baruchel A, Conter V, Otten J, Ohara A, Versluys A, Escherich G, Heyman M, Silverman L, Horibe K, Mann G, Camitta B, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M
NEW ENGL J MED. 2012;366(15):1371-1381.

2011

Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey.
Bienemann K, Burkhardt B, Modlich S, Meyer U, Möricke A, Bienemann K, Mauz-Körholz C, Escherich G, Zimmermann M, Körholz D, Janka-Schaub G, Schrappe M, Reiter A, Borkhardt A
BRIT J HAEMATOL. 2011;155(4):468-476.

Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia.
Escherich G, Richards S, Stork L, Vora A
LEUKEMIA. 2011;25(6):953-959.

The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
Escherich G, Troeger A, Gobel U, Graubner U, Pekrun A, Jorch N, Kaspers G, Zimmermann M, Zur Stadt U, Kazemir K, Pieters R, Horstmann M, Denboer M, Janka-Schaub G
HAEMATOLOGICA. 2011;96(6):854-862.

Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group.
von Stackelberg A, Völzke E, Kühl J, Seeger K, Schrauder A, Escherich G, Henze G, Tallen G, Group A
EUR J CANCER. 2011;47(1):90-97.

2010

Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.
Aricò M, Schrappe M, Hunger S, Carroll W, Conter V, Galimberti S, Manabe A, Saha V, Baruchel A, Vettenranta K, Horibe K, Benoit Y, Pieters R, Escherich G, Silverman L, Pui C, Valsecchi M
J CLIN ONCOL. 2010;28(31):4755-4761.

Cooperative study group for childhood acute lymphoblastic leukaemia (COALL)
Escherich G, Horstmann M, Zimmermann M, Janka-Schaub G
LEUKEMIA. 2010;24(2):298-308.

Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, Ebell W, Escherich G, Schrappe M, Klingebiel T, Fengler R, Henze G, von Stackelberg A
J CLIN ONCOL. 2010;28(14):2339-2347.

2009

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.
Den B, Monique L, Slegtenhorst v, Marjon [, Menezes D, Renée X, Cheok [, Meyling H, Buijs-Gladdines [, Jessica G, Peters [, Susan T, Zutven V, Laura J, Beverloo [, Berna H, Spek V, Peter J, Escherich G, Gaby [, Horstmann M, Martin A, Janka-Schaub G, Gritta E, Kamps [, Willem A, Evans [, William E, Pieters [, Rob [
LANCET ONCOL. 2009;10(2):125-134.

Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.
Escherich G, Horstmann M, Zimmermann M, Janka-Schaub G
LEUKEMIA. 2009.

2008

Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, Möricke A, Henze G, von Stackelberg A
EUR J CANCER. 2008;44(2):257-268.

Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia.
Graubner U, Porzig S, Jorch N, Kolb R, Wessalowski R, Escherich G, Janka-Schaub G
PEDIATR BLOOD CANCER. 2008;50(2):259-263.

High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95.
Troeger A, Glouchkova L, Ackermann B, Escherich G, Meisel R, Hanenberg H, Boer d, Monique L, Janka-Schaub G, Janka-Schaub G, Goebel U, Laws H, Dilloo D
BLOOD. 2008;112(4):1028-1034.

Reduced expression and defective modulation of TNF receptor/ligand family molecules on proB-ALL blasts.
Troeger A, Glouchkova L, Escherich G, Siepermann M, Hanenberg H, Janka-Schaub G, Göbel U, Ackermann B, Dilloo D
KLIN PADIATR. 2008;220(6):353-357.

2007

Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
Escherich G, Göbel U, Jorch N, Spaar H, Janka-Schaub G
KLIN PADIATR. 2007;219(3):134-138.

High nerve growth factor receptor (p75NTR) expression is a favourable prognostic factor in paediatric B cell precursor-acute lymphoblastic leukaemia.
Troeger A, Gudowius S, Escherich G, Boer d, Monique L, Glouchkova L, Ackermann B, Meisel R, Laws H, Groeger M, Wessalowski R, Willers R, Harbott J, Pieters R, Janka-Schaub G, Janka-Schaub G, Hanenberg H, Dilloo D
BRIT J HAEMATOL. 2007;139(3):450-457.

Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia.
Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, Moritz T, Laws H, Hanenberg H, Goebel U, Janka-Schaub G, Mahotka C, Dilloo D
HAEMATOLOGICA. 2007;92(8):1043-1050.

Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia.
Tröger A, Siepermann M, Mahotka C, Wethkamp N, Bülle H, Laws H, Escherich G, Janka-Schaub G, Göbel U, Dilloo D
KLIN PADIATR. 2007;219(3):127-133.

2005

Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Horstmann M, Hassenpflug W, Udo Z, Escherich G, Janka-Schaub G, Kabisch H
HAEMATOLOGICA. 2005;90(12):1701-1703.

2003

High-performance liquid chromatographic assay of metabolites of thioguanine and mercaptopurine in capillary blood.
Erb N, Haverland U, Harms D, Escherich G, Janka-Schaub G
J CHROMATOGR B ANALYT TECHNOL BIOMED LIFE SCI. 2003;796(1):87-94.

1995

[Intraspinal metastasis of stage I anaplastic Wilms tumor]
Wiegel T, Grzyska U, Schwarz R, Escherich G
STRAHLENTHER ONKOL. 1995;171(5):296-299.

Letzte Aktualisierung aus dem FIS: 17.07.2017 - 00:04 Uhr